Dinoprost

Overview

Dinoprost (Lutalyse®) is naturally occurring prostaglandin F2-alpha (PGF2α) used in veterinary medicine primarily for its luteolytic and uterotonic effects in dogs and cats. It is most commonly utilized in reproductive medicine, particularly for the management of open pyometra and, less commonly, for pregnancy termination or parturition induction when clinically indicated.

The drug has a rapid onset of action following administration, with short systemic persistence due to rapid metabolism and clearance. Clinical effects are typically observed within minutes to hours, particularly those related to smooth muscle stimulation of the uterus and gastrointestinal tract.

Mechanism of Action (MOA): Dinoprost acts by stimulating myometrial contractions and promoting cervical relaxation, facilitating uterine evacuation. It also induces luteolysis by inhibiting steroidogenesis in the corpus luteum, leading to a decline in progesterone levels. These combined effects support its role in conditions requiring uterine clearance, such as open pyometra.

Indications

Dinoprost is used in dogs and cats primarily for its effects on the uterus and corpus luteum, making it useful in selected reproductive conditions where uterine evacuation or luteolysis is required. Its use should be limited to stable patients under close veterinary supervision.

• Open pyometra (primary indication): Dinoprost is a SECOND-LINE option for medical management of open pyometra — aglepristone is the first treatment of choice . When aglepristone is unavailable or has failed, dinoprost stimulates uterine contractions and cervical relaxation to facilitate evacuation of purulent uterine contents. Ovariohysterectomy remains the gold standard for most patients.
• Pregnancy termination (abortifacient use): May be used to induce abortion through luteolysis and reduction of progesterone levels when termination of pregnancy is medically indicated.
• Parturition induction: Can be used in late gestation to induce parturition by promoting uterine contractions and cervical dilation, although this is less commonly performed in small animal practice.

Dosage (Reference)

Dog

In dogs, dinoprost is primarily used for the medical management of open pyometra. Dogs are more sensitive to its effects compared to other species, so careful dose selection and close monitoring are essential.

Cat

In cats, dinoprost is used for medical management of open-cervix pyometra in breeding queens. Cats are highly sensitive to PGF2α side effects — start at the lower dose and monitor closely for 1–2 hours post-injection. Confirm open cervix before administering. Ovariohysterectomy remains the gold standard for most patients.

Warnings & Precautions

Dinoprost is a potent prostaglandin with significant effects on smooth muscle and the cardiovascular and respiratory systems. Careful patient selection and strict adherence to administration guidelines are essential to minimize the risk of serious adverse outcomes.

• Pregnancy: Contraindicated in pregnant animals unless used intentionally for abortion or parturition induction due to its strong luteolytic and uterotonic effects.
• Route of administration: Must not be administered intravenously; improper administration may increase the risk of severe systemic effects.
• Cardiopulmonary disease: Use with extreme caution in animals with pre-existing cardiac or respiratory disorders, as the drug may exacerbate tachycardia, dyspnea, or bronchoconstriction.
• Bronchoconstrictive disorders: Contraindicated in patients with conditions such as asthma due to the risk of bronchospasm.
• Brachycephalic breeds: Brachycephalic breeds: contraindicated. Bulldogs, pugs, French bulldogs and other brachycephalic breeds are predisposed to bronchospasm and should not receive PGF2α . Use an alternative protocol (aglepristone) in these patients.
• Geriatric or debilitated patients: Increased risk of adverse effects; use cautiously or avoid in animals older than 8 years or those with systemic illness (e.g., hepatic, renal, septic, or peritonitis cases).
• Closed-cervix pyometra: Considered a relative contraindication by some clinicians due to the risk of uterine rupture or ineffective drainage.
• Pyometra protocol age limit: Pyometra protocol age restriction: the dinoprost pyometra protocol is restricted to bitches 6 years of age or younger that have an open cervix, are clinically stable, and where preservation of reproductive potential is desired.
• Monitoring requirement: Dogs and cats should be closely monitored after administration for cardiorespiratory changes and systemic adverse effects, particularly at higher doses.
• Human safety: Classified as a hazardous drug; avoid skin contact and inhalation. Pregnant women and individuals with asthma should not handle the drug due to risk of absorption and bronchospasm.
• Client administration: Not recommended for home use due to potential for serious adverse effects in both the animal and the handler.

Drug Interactions

Clinically relevant interactions with dinoprost are primarily related to its effects on uterine contractility and luteal function. When used with other reproductive or hormonal agents, the overall response may be enhanced or reduced depending on the mechanism of the concurrent drug.

• Other oxytocic agents: Concurrent use may enhance uterine contractility and increase the overall pharmacologic effect of dinoprost; use cautiously and monitor for excessive uterine activity or adverse effects.
• Oxytocin (specific risk): Oxytocin: when used concurrently with dinoprost there is a risk of uterine rupture due to combined uterotonic effect (.
• NSAIDs: NSAIDs (e.g. carprofen, meloxicam): per the dinoprost product label, NSAIDs should not be used concurrently because they inhibit prostaglandin synthesis. Practical risk for exogenous dinoprost may be limited, but the label warning stands.
• Progestins: May reduce or antagonize the luteolytic and therapeutic effects of dinoprost due to opposing hormonal actions.

Side Effects & Overdose

Side Effects

Adverse effects of dinoprost in dogs and cats are common and primarily related to its stimulatory effects on smooth muscle. The severity of these effects is generally dose-dependent and may vary between patients.

• Gastrointestinal effects: Abdominal pain, emesis, defecation, and urination are frequently observed following administration.
• Respiratory effects: Dyspnea and panting may occur, particularly in sensitive or compromised patients.
• Cardiovascular effects: Tachycardia may develop as part of the systemic response.
• Neurologic/behavioral signs: Restlessness, anxiety, and discomfort are common; cats may show increased vocalization and intense grooming behavior.
• Ocular effects: Pupillary dilation followed by constriction may be observed.
• Systemic signs: Fever and hypersalivation may occur.
• Onset and duration: Clinical signs typically appear within 5–120 minutes after administration and usually persist for 20–30 minutes.
• Severe reactions: Death has been reported, particularly in dogs, especially with higher doses or increased sensitivity.

Overdose

Dogs are more sensitive to dinoprost toxicity compared to many other species. Overdose can lead to exaggerated pharmacologic effects and may require prompt supportive care.

• Increased toxicity risk in dogs: The reported LD50 in the bitch is 5.13 mg/kg SC — only ~5× the recommended clinical dose .. Deaths have occurred in dogs given doses above this margin. NEVER exceed the recommended dose; small dosing errors can be fatal.
• Exaggerated adverse effects: Severe gastrointestinal, cardiovascular, and respiratory signs may occur following overdose.
• Systemic complications: Marked hyperthermia and profound systemic distress may develop in severe cases.
• Management: Treatment is supportive and based on clinical signs, including monitoring and stabilization of cardiorespiratory function.
• Monitoring: Close observation is required in suspected overdose cases due to the potential for rapid onset of clinical signs.

Key Notes

Practical clinical considerations that can improve the safe and effective use of dinoprost in dogs and cats in everyday veterinary practice:

• Case selection is critical: Medical management with dinoprost is best reserved for stable patients where uterine evacuation is feasible and closely monitored.
• Clinical response monitoring: Treatment success should be assessed based on clinical improvement and uterine clearance rather than fixed treatment duration alone.
• Use as part of a multimodal approach: Often combined with supportive care and adjunctive therapies to improve outcomes in reproductive conditions.
• Individual variability: Response and tolerance vary widely between patients; dosing intervals and continuation should be tailored based on patient response.
• Short duration of action: Rapid metabolism means repeated dosing is required to maintain therapeutic effect.
• Clinical setting use: Best administered in a controlled clinical environment where monitoring and intervention are readily available.
• Owner expectations: Clients should be informed that treatment may require multiple doses and close follow-up to ensure successful resolution.
• Outcome statistics: Outcome statistics : medical treatment success ~86% in bitches and ~95% in queens. Recurrence rate at subsequent heats ranges 20–65% depending on age, parity, and pre-existing uterine pathology. Mortality rate ~4% in bitches and ~8% in queens. Counsel owners that breeding at the next heat reduces recurrence risk.